 | • レポートコード：GIR-107A12359 • 出版社/出版日：GlobalInfoResearch / 2021年7月 ※2024年版があります。お問い合わせください。 • レポート形態：英文、PDF、92ページ • 納品方法：Eメール（納期：2~3日） • 産業分類：医療 |
| Single User | ￥515,040 (USD3,480) | ▷ お問い合わせ |
| Multi User | ￥772,560 (USD5,220) | ▷ お問い合わせ |
| Corporate User | ￥1,030,080 (USD6,960) | ▷ お問い合わせ |
• お支払方法：銀行振込（納品後、ご請求書送付）
レポート概要
| 当調査資料では、ヒトマイクロバイオーム薬物・診断のグローバル市場について調査・分析し、2021年から2026年までの市場予測をまとめております。ヒトマイクロバイオーム薬物・診断の種類別市場規模（治療、診断）、用途別市場規模（臨床研究所、病院、外科センター、その他）、地域別市場規模（北米、アメリカ、ヨーロッパ、アジア、中国、日本、東南アジア、南米、中東、アフリカなど）、市場動向、企業別販売量と市場シェア、販売チャネルなどの情報を掲載しています。 ・ヒトマイクロバイオーム薬物・診断の市場概要 ・企業情報（企業概要、製品概要、販売量、価格、売上）：Second Genome、Enterome Bioscience、Yakult、Dowdupont、Vedanta BioSciences、Metabiomics Corporation、ViThera Pharmaceuticals、MicroBiome Therapeutics、Osel、Merck ・企業別市場シェア ・地域別市場分析2016年-2026年 ・種類別分析2016年-2026年：治療、診断 ・用途別分析2016年-2026年：臨床研究所、病院、外科センター、その他 ・ヒトマイクロバイオーム薬物・診断の北米市場規模2016年-2026年：アメリカ、カナダ、メキシコ ・ヒトマイクロバイオーム薬物・診断のヨーロッパ市場規模2016年-2026年：ドイツ、イギリス、フランス、ロシア、イタリア ・ヒトマイクロバイオーム薬物・診断のアジア市場規模2016年-2026年：中国、日本、韓国、インド、東南アジア、オーストラリア ・ヒトマイクロバイオーム薬物・診断の南米市場規模2016年-2026年：ブラジル、アルゼンチン ・ヒトマイクロバイオーム薬物・診断の中東・アフリカ市場規模2016年-2026年：サウジアラビア、トルコ、エジプト、南アフリカ ・販売チャネル、流通業者・代理店、顧客リスト ・調査の結果・結論 |
The Human Microbiome Based Drugs and Diagnostics market report provides a detailed analysis of global market size, regional and country-level market size, segmentation market growth, market share, competitive Landscape, sales analysis, impact of domestic and global market players, value chain optimization, trade regulations, recent developments, opportunities analysis, strategic market growth analysis, product launches, area marketplace expanding, and technological innovations.
According to our latest research, the global Human Microbiome Based Drugs and Diagnostics size is estimated to be USD 1241.6 million in 2026 from USD 851.9 million in 2020, with a change XX% between 2020 and 2021. The global Human Microbiome Based Drugs and Diagnostics market size is expected to grow at a CAGR of 9.9% for the next five years.
Market segmentation
Human Microbiome Based Drugs and Diagnostics market is split by Type and by Application. For the period 2016-2026, the growth among segments provide accurate calculations and forecasts for revenue by Type and by Application. This analysis can help you expand your business by targeting qualified niche markets.
Market segment by Type, covers
Therapeutics
Diagnostics
Market segment by Application, can be divided into
Clinical Research Institutes
Hospital
Surgical Centers
Others
Market segment by players, this report covers
Second Genome
Enterome Bioscience
Yakult
Dowdupont
Vedanta BioSciences
Metabiomics Corporation
ViThera Pharmaceuticals
MicroBiome Therapeutics
Osel
Merck
Market segment by regions, regional analysis covers
North America (United States, Canada, and Mexico)
Europe (Germany, France, UK, Russia, Italy, and Rest of Europe)
Asia-Pacific (China, Japan, South Korea, India, Southeast Asia, Australia, and Rest of Asia-Pacific)
South America (Brazil, Argentina, Rest of South America)
Middle East & Africa (Turkey, Saudi Arabia, UAE, Rest of Middle East & Africa)
The content of the study subjects, includes a total of 12 chapters:
Chapter 1, to describe Human Microbiome Based Drugs and Diagnostics product scope, market overview, market opportunities, market driving force and market risks.
Chapter 2, to profile the top players of Human Microbiome Based Drugs and Diagnostics, with revenue, gross margin and global market share of Human Microbiome Based Drugs and Diagnostics from 2019 to 2021.
Chapter 3, the Human Microbiome Based Drugs and Diagnostics competitive situation, revenue and global market share of top players are analyzed emphatically by landscape contrast.
Chapter 4 and 5, to segment the market size by type and application, with revenue and growth rate by type, application, from 2016 to 2026.
Chapter 6, 7, 8, 9, and 10, to break the market size data at the country level, with revenue and market share for key countries in the world, from 2016 to 2021.and Human Microbiome Based Drugs and Diagnostics market forecast, by regions, type and application, with revenue, from 2021 to 2026.
Chapter 11 and 12, to describe Human Microbiome Based Drugs and Diagnostics research findings and conclusion, appendix and data source.
1 Market Overview
1.1 Product Overview and Scope of Human Microbiome Based Drugs and Diagnostics
1.2 Classification of Human Microbiome Based Drugs and Diagnostics by Type
1.2.1 Overview: Global Human Microbiome Based Drugs and Diagnostics Market Size by Type: 2020 Versus 2021 Versus 2026
1.2.2 Global Human Microbiome Based Drugs and Diagnostics Revenue Market Share by Type in 2020
1.2.3 Therapeutics
1.2.4 Diagnostics
1.3 Global Human Microbiome Based Drugs and Diagnostics Market by Application
1.3.1 Overview: Global Human Microbiome Based Drugs and Diagnostics Market Size by Application: 2020 Versus 2021 Versus 2026
1.3.2 Clinical Research Institutes
1.3.3 Hospital
1.3.4 Surgical Centers
1.3.5 Others
1.4 Global Human Microbiome Based Drugs and Diagnostics Market Size & Forecast
1.5 Global Human Microbiome Based Drugs and Diagnostics Market Size and Forecast by Region
1.5.1 Global Human Microbiome Based Drugs and Diagnostics Market Size by Region: 2016 VS 2021 VS 2026
1.5.2 Global Human Microbiome Based Drugs and Diagnostics Market Size by Region, (2016-2021)
1.5.3 North America Human Microbiome Based Drugs and Diagnostics Market Size and Prospect (2016-2026)
1.5.4 Europe Human Microbiome Based Drugs and Diagnostics Market Size and Prospect (2016-2026)
1.5.5 Asia-Pacific Human Microbiome Based Drugs and Diagnostics Market Size and Prospect (2016-2026)
1.5.6 South America Human Microbiome Based Drugs and Diagnostics Market Size and Prospect (2016-2026)
1.5.7 Middle East and Africa Human Microbiome Based Drugs and Diagnostics Market Size and Prospect (2016-2026)
1.6 Market Drivers, Restraints and Trends
1.6.1 Human Microbiome Based Drugs and Diagnostics Market Drivers
1.6.2 Human Microbiome Based Drugs and Diagnostics Market Restraints
1.6.3 Human Microbiome Based Drugs and Diagnostics Trends Analysis
2 Company Profiles
2.1 Second Genome
2.1.1 Second Genome Details
2.1.2 Second Genome Major Business
2.1.3 Second Genome Human Microbiome Based Drugs and Diagnostics Product and Solutions
2.1.4 Second Genome Human Microbiome Based Drugs and Diagnostics Revenue, Gross Margin and Market Share (2019-2021)
2.1.5 Second Genome Recent Developments and Future Plans
2.2 Enterome Bioscience
2.2.1 Enterome Bioscience Details
2.2.2 Enterome Bioscience Major Business
2.2.3 Enterome Bioscience Human Microbiome Based Drugs and Diagnostics Product and Solutions
2.2.4 Enterome Bioscience Human Microbiome Based Drugs and Diagnostics Revenue, Gross Margin and Market Share (2019-2021)
2.2.5 Enterome Bioscience Recent Developments and Future Plans
2.3 Yakult
2.3.1 Yakult Details
2.3.2 Yakult Major Business
2.3.3 Yakult Human Microbiome Based Drugs and Diagnostics Product and Solutions
2.3.4 Yakult Human Microbiome Based Drugs and Diagnostics Revenue, Gross Margin and Market Share (2019-2021)
2.3.5 Yakult Recent Developments and Future Plans
2.4 Dowdupont
2.4.1 Dowdupont Details
2.4.2 Dowdupont Major Business
2.4.3 Dowdupont Human Microbiome Based Drugs and Diagnostics Product and Solutions
2.4.4 Dowdupont Human Microbiome Based Drugs and Diagnostics Revenue, Gross Margin and Market Share (2019-2021)
2.4.5 Dowdupont Recent Developments and Future Plans
2.5 Vedanta BioSciences
2.5.1 Vedanta BioSciences Details
2.5.2 Vedanta BioSciences Major Business
2.5.3 Vedanta BioSciences Human Microbiome Based Drugs and Diagnostics Product and Solutions
2.5.4 Vedanta BioSciences Human Microbiome Based Drugs and Diagnostics Revenue, Gross Margin and Market Share (2019-2021)
2.5.5 Vedanta BioSciences Recent Developments and Future Plans
2.6 Metabiomics Corporation
2.6.1 Metabiomics Corporation Details
2.6.2 Metabiomics Corporation Major Business
2.6.3 Metabiomics Corporation Human Microbiome Based Drugs and Diagnostics Product and Solutions
2.6.4 Metabiomics Corporation Human Microbiome Based Drugs and Diagnostics Revenue, Gross Margin and Market Share (2019-2021)
2.6.5 Metabiomics Corporation Recent Developments and Future Plans
2.7 ViThera Pharmaceuticals
2.7.1 ViThera Pharmaceuticals Details
2.7.2 ViThera Pharmaceuticals Major Business
2.7.3 ViThera Pharmaceuticals Human Microbiome Based Drugs and Diagnostics Product and Solutions
2.7.4 ViThera Pharmaceuticals Human Microbiome Based Drugs and Diagnostics Revenue, Gross Margin and Market Share (2019-2021)
2.7.5 ViThera Pharmaceuticals Recent Developments and Future Plans
2.8 MicroBiome Therapeutics
2.8.1 MicroBiome Therapeutics Details
2.8.2 MicroBiome Therapeutics Major Business
2.8.3 MicroBiome Therapeutics Human Microbiome Based Drugs and Diagnostics Product and Solutions
2.8.4 MicroBiome Therapeutics Human Microbiome Based Drugs and Diagnostics Revenue, Gross Margin and Market Share (2019-2021)
2.8.5 MicroBiome Therapeutics Recent Developments and Future Plans
2.9 Osel
2.9.1 Osel Details
2.9.2 Osel Major Business
2.9.3 Osel Human Microbiome Based Drugs and Diagnostics Product and Solutions
2.9.4 Osel Human Microbiome Based Drugs and Diagnostics Revenue, Gross Margin and Market Share (2019-2021)
2.9.5 Osel Recent Developments and Future Plans
2.10 Merck
2.10.1 Merck Details
2.10.2 Merck Major Business
2.10.3 Merck Human Microbiome Based Drugs and Diagnostics Product and Solutions
2.10.4 Merck Human Microbiome Based Drugs and Diagnostics Revenue, Gross Margin and Market Share (2019-2021)
2.10.5 Merck Recent Developments and Future Plans
3 Market Competition, by Players
3.1 Global Human Microbiome Based Drugs and Diagnostics Revenue and Share by Players (2019-2021)
3.2 Market Concentration Rate
3.2.1 Top 3 Human Microbiome Based Drugs and Diagnostics Players Market Share
3.2.2 Top 10 Human Microbiome Based Drugs and Diagnostics Players Market Share
3.2.3 Market Competition Trend
3.3 Human Microbiome Based Drugs and Diagnostics Players Head Office, Products and Services Provided
3.4 Mergers & Acquisitions
3.5 New Entrants and Expansion Plans
4 Market Size Segment by Type
4.1 Global Human Microbiome Based Drugs and Diagnostics Revenue and Market Share by Type (2016-2021)
4.2 Global Human Microbiome Based Drugs and Diagnostics Market Forecast by Type (2021-2026)
5 Market Size Segment by Application
5.1 Global Human Microbiome Based Drugs and Diagnostics Revenue Market Share by Application (2016-2021)
5.2 Human Microbiome Based Drugs and Diagnostics Market Forecast by Application (2021-2026)
6 North America by Country, by Type, and by Application
6.1 North America Human Microbiome Based Drugs and Diagnostics Revenue by Type (2016-2026)
6.2 North America Human Microbiome Based Drugs and Diagnostics Revenue by Application (2016-2026)
6.3 North America Human Microbiome Based Drugs and Diagnostics Market Size by Country
6.3.1 North America Human Microbiome Based Drugs and Diagnostics Revenue by Country (2016-2026)
6.3.2 United States Human Microbiome Based Drugs and Diagnostics Market Size and Forecast (2016-2026)
6.3.3 Canada Human Microbiome Based Drugs and Diagnostics Market Size and Forecast (2016-2026)
6.3.4 Mexico Human Microbiome Based Drugs and Diagnostics Market Size and Forecast (2016-2026)
7 Europe by Country, by Type, and by Application
7.1 Europe Human Microbiome Based Drugs and Diagnostics Revenue by Type (2016-2026)
7.2 Europe Human Microbiome Based Drugs and Diagnostics Revenue by Application (2016-2026)
7.3 Europe Human Microbiome Based Drugs and Diagnostics Market Size by Country
7.3.1 Europe Human Microbiome Based Drugs and Diagnostics Revenue by Country (2016-2026)
7.3.2 Germany Human Microbiome Based Drugs and Diagnostics Market Size and Forecast (2016-2026)
7.3.3 France Human Microbiome Based Drugs and Diagnostics Market Size and Forecast (2016-2026)
7.3.4 United Kingdom Human Microbiome Based Drugs and Diagnostics Market Size and Forecast (2016-2026)
7.3.5 Russia Human Microbiome Based Drugs and Diagnostics Market Size and Forecast (2016-2026)
7.3.6 Italy Human Microbiome Based Drugs and Diagnostics Market Size and Forecast (2016-2026)
8 Asia-Pacific by Region, by Type, and by Application
8.1 Asia-Pacific Human Microbiome Based Drugs and Diagnostics Revenue by Type (2016-2026)
8.2 Asia-Pacific Human Microbiome Based Drugs and Diagnostics Revenue by Application (2016-2026)
8.3 Asia-Pacific Human Microbiome Based Drugs and Diagnostics Market Size by Region
8.3.1 Asia-Pacific Human Microbiome Based Drugs and Diagnostics Revenue by Region (2016-2026)
8.3.2 China Human Microbiome Based Drugs and Diagnostics Market Size and Forecast (2016-2026)
8.3.3 Japan Human Microbiome Based Drugs and Diagnostics Market Size and Forecast (2016-2026)
8.3.4 South Korea Human Microbiome Based Drugs and Diagnostics Market Size and Forecast (2016-2026)
8.3.5 India Human Microbiome Based Drugs and Diagnostics Market Size and Forecast (2016-2026)
8.3.6 Southeast Asia Human Microbiome Based Drugs and Diagnostics Market Size and Forecast (2016-2026)
8.3.7 Australia Human Microbiome Based Drugs and Diagnostics Market Size and Forecast (2016-2026)
9 South America by Country, by Type, and by Application
9.1 South America Human Microbiome Based Drugs and Diagnostics Revenue by Type (2016-2026)
9.2 South America Human Microbiome Based Drugs and Diagnostics Revenue by Application (2016-2026)
9.3 South America Human Microbiome Based Drugs and Diagnostics Market Size by Country
9.3.1 South America Human Microbiome Based Drugs and Diagnostics Revenue by Country (2016-2026)
9.3.2 Brazil Human Microbiome Based Drugs and Diagnostics Market Size and Forecast (2016-2026)
9.3.3 Argentina Human Microbiome Based Drugs and Diagnostics Market Size and Forecast (2016-2026)
10 Middle East & Africa by Country, by Type, and by Application
10.1 Middle East & Africa Human Microbiome Based Drugs and Diagnostics Revenue by Type (2016-2026)
10.2 Middle East & Africa Human Microbiome Based Drugs and Diagnostics Revenue by Application (2016-2026)
10.3 Middle East & Africa Human Microbiome Based Drugs and Diagnostics Market Size by Country
10.3.1 Middle East & Africa Human Microbiome Based Drugs and Diagnostics Revenue by Country (2016-2026)
10.3.2 Turkey Human Microbiome Based Drugs and Diagnostics Market Size and Forecast (2016-2026)
10.3.3 Saudi Arabia Human Microbiome Based Drugs and Diagnostics Market Size and Forecast (2016-2026)
10.3.4 UAE Human Microbiome Based Drugs and Diagnostics Market Size and Forecast (2016-2026)
11 Research Findings and Conclusion
12 Appendix
12.1 Methodology
12.2 Research Process and Data Source
12.3 Disclaimer
Table 1. Global Human Microbiome Based Drugs and Diagnostics Revenue by Type, (USD Million), 2020 VS 2021 VS 2026
Table 2. Global Human Microbiome Based Drugs and Diagnostics Revenue by Application, (USD Million), 2020 VS 2021 VS 2026
Table 3. Global Market Human Microbiome Based Drugs and Diagnostics Revenue (Million USD) Comparison by Region (2016 VS 2021 VS 2026)
Table 4. Global Human Microbiome Based Drugs and Diagnostics Revenue (USD Million) by Region (2016-2021)
Table 5. Global Human Microbiome Based Drugs and Diagnostics Revenue Market Share by Region (2021-2026)
Table 6. Second Genome Corporate Information, Head Office, and Major Competitors
Table 7. Second Genome Major Business
Table 8. Second Genome Human Microbiome Based Drugs and Diagnostics Product and Solutions
Table 9. Second Genome Human Microbiome Based Drugs and Diagnostics Revenue (USD Million), Gross Margin and Market Share (2019-2021)
Table 10. Enterome Bioscience Corporate Information, Head Office, and Major Competitors
Table 11. Enterome Bioscience Major Business
Table 12. Enterome Bioscience Human Microbiome Based Drugs and Diagnostics Product and Solutions
Table 13. Enterome Bioscience Human Microbiome Based Drugs and Diagnostics Revenue (USD Million), Gross Margin and Market Share (2019-2021)
Table 14. Yakult Corporate Information, Head Office, and Major Competitors
Table 15. Yakult Major Business
Table 16. Yakult Human Microbiome Based Drugs and Diagnostics Product and Solutions
Table 17. Yakult Human Microbiome Based Drugs and Diagnostics Revenue (USD Million), Gross Margin and Market Share (2019-2021)
Table 18. Dowdupont Corporate Information, Head Office, and Major Competitors
Table 19. Dowdupont Major Business
Table 20. Dowdupont Human Microbiome Based Drugs and Diagnostics Product and Solutions
Table 21. Dowdupont Human Microbiome Based Drugs and Diagnostics Revenue (USD Million), Gross Margin and Market Share (2019-2021)
Table 22. Vedanta BioSciences Corporate Information, Head Office, and Major Competitors
Table 23. Vedanta BioSciences Major Business
Table 24. Vedanta BioSciences Human Microbiome Based Drugs and Diagnostics Product and Solutions
Table 25. Vedanta BioSciences Human Microbiome Based Drugs and Diagnostics Revenue (USD Million), Gross Margin and Market Share (2019-2021)
Table 26. Metabiomics Corporation Corporate Information, Head Office, and Major Competitors
Table 27. Metabiomics Corporation Major Business
Table 28. Metabiomics Corporation Human Microbiome Based Drugs and Diagnostics Product and Solutions
Table 29. Metabiomics Corporation Human Microbiome Based Drugs and Diagnostics Revenue (USD Million), Gross Margin and Market Share (2019-2021)
Table 30. ViThera Pharmaceuticals Corporate Information, Head Office, and Major Competitors
Table 31. ViThera Pharmaceuticals Major Business
Table 32. ViThera Pharmaceuticals Human Microbiome Based Drugs and Diagnostics Product and Solutions
Table 33. ViThera Pharmaceuticals Human Microbiome Based Drugs and Diagnostics Revenue (USD Million), Gross Margin and Market Share (2019-2021)
Table 34. MicroBiome Therapeutics Corporate Information, Head Office, and Major Competitors
Table 35. MicroBiome Therapeutics Major Business
Table 36. MicroBiome Therapeutics Human Microbiome Based Drugs and Diagnostics Product and Solutions
Table 37. MicroBiome Therapeutics Human Microbiome Based Drugs and Diagnostics Revenue (USD Million), Gross Margin and Market Share (2019-2021)
Table 38. Osel Corporate Information, Head Office, and Major Competitors
Table 39. Osel Major Business
Table 40. Osel Human Microbiome Based Drugs and Diagnostics Product and Solutions
Table 41. Osel Human Microbiome Based Drugs and Diagnostics Revenue (USD Million), Gross Margin and Market Share (2019-2021)
Table 42. Merck Corporate Information, Head Office, and Major Competitors
Table 43. Merck Major Business
Table 44. Merck Human Microbiome Based Drugs and Diagnostics Product and Solutions
Table 45. Merck Human Microbiome Based Drugs and Diagnostics Revenue (USD Million), Gross Margin and Market Share (2019-2021)
Table 46. Global Human Microbiome Based Drugs and Diagnostics Revenue (USD Million) by Players (2019-2021)
Table 47. Global Human Microbiome Based Drugs and Diagnostics Revenue Share by Players (2019-2021)
Table 48. Breakdown of Human Microbiome Based Drugs and Diagnostics by Company Type (Tier 1, Tier 2 and Tier 3)
Table 49. Human Microbiome Based Drugs and Diagnostics Players Head Office, Products and Services Provided
Table 50. Human Microbiome Based Drugs and Diagnostics Mergers & Acquisitions in the Past Five Years
Table 51. Human Microbiome Based Drugs and Diagnostics New Entrants and Expansion Plans
Table 52. Global Human Microbiome Based Drugs and Diagnostics Revenue (USD Million) by Type (2016-2021)
Table 53. Global Human Microbiome Based Drugs and Diagnostics Revenue Share by Type (2016-2021)
Table 54. Global Human Microbiome Based Drugs and Diagnostics Revenue Forecast by Type (2021-2026)
Table 55. Global Human Microbiome Based Drugs and Diagnostics Revenue by Application (2016-2021)
Table 56. Global Human Microbiome Based Drugs and Diagnostics Revenue Forecast by Application (2021-2026)
Table 57. North America Human Microbiome Based Drugs and Diagnostics Revenue by Type (2016-2021) & (USD Million)
Table 58. North America Human Microbiome Based Drugs and Diagnostics Revenue by Type (2021-2026) & (USD Million)
Table 59. North America Human Microbiome Based Drugs and Diagnostics Revenue by Application (2016-2021) & (USD Million)
Table 60. North America Human Microbiome Based Drugs and Diagnostics Revenue by Application (2021-2026) & (USD Million)
Table 61. North America Human Microbiome Based Drugs and Diagnostics Revenue by Country (2016-2021) & (USD Million)
Table 62. North America Human Microbiome Based Drugs and Diagnostics Revenue by Country (2021-2026) & (USD Million)
Table 63. Europe Human Microbiome Based Drugs and Diagnostics Revenue by Type (2016-2021) & (USD Million)
Table 64. Europe Human Microbiome Based Drugs and Diagnostics Revenue by Type (2021-2026) & (USD Million)
Table 65. Europe Human Microbiome Based Drugs and Diagnostics Revenue by Application (2016-2021) & (USD Million)
Table 66. Europe Human Microbiome Based Drugs and Diagnostics Revenue by Application (2021-2026) & (USD Million)
Table 67. Europe Human Microbiome Based Drugs and Diagnostics Revenue by Country (2016-2021) & (USD Million)
Table 68. Europe Human Microbiome Based Drugs and Diagnostics Revenue by Country (2021-2026) & (USD Million)
Table 69. Asia-Pacific Human Microbiome Based Drugs and Diagnostics Revenue by Type (2016-2021) & (USD Million)
Table 70. Asia-Pacific Human Microbiome Based Drugs and Diagnostics Revenue by Type (2021-2026) & (USD Million)
Table 71. Asia-Pacific Human Microbiome Based Drugs and Diagnostics Revenue by Application (2016-2021) & (USD Million)
Table 72. Asia-Pacific Human Microbiome Based Drugs and Diagnostics Revenue by Application (2021-2026) & (USD Million)
Table 73. Asia-Pacific Human Microbiome Based Drugs and Diagnostics Revenue by Region (2016-2021) & (USD Million)
Table 74. Asia-Pacific Human Microbiome Based Drugs and Diagnostics Revenue by Region (2021-2026) & (USD Million)
Table 75. South America Human Microbiome Based Drugs and Diagnostics Revenue by Type (2016-2021) & (USD Million)
Table 76. South America Human Microbiome Based Drugs and Diagnostics Revenue by Type (2021-2026) & (USD Million)
Table 77. South America Human Microbiome Based Drugs and Diagnostics Revenue by Application (2016-2021) & (USD Million)
Table 78. South America Human Microbiome Based Drugs and Diagnostics Revenue by Application (2021-2026) & (USD Million)
Table 79. South America Human Microbiome Based Drugs and Diagnostics Revenue by Country (2016-2021) & (USD Million)
Table 80. South America Human Microbiome Based Drugs and Diagnostics Revenue by Country (2021-2026) & (USD Million)
Table 81. Middle East & Africa Human Microbiome Based Drugs and Diagnostics Revenue by Type (2016-2021) & (USD Million)
Table 82. Middle East & Africa Human Microbiome Based Drugs and Diagnostics Revenue by Type (2021-2026) & (USD Million)
Table 83. Middle East & Africa Human Microbiome Based Drugs and Diagnostics Revenue by Application (2016-2021) & (USD Million)
Table 84. Middle East & Africa Human Microbiome Based Drugs and Diagnostics Revenue by Application (2021-2026) & (USD Million)
Table 85. Middle East & Africa Human Microbiome Based Drugs and Diagnostics Revenue by Country (2016-2021) & (USD Million)
Table 86. Middle East & Africa Human Microbiome Based Drugs and Diagnostics Revenue by Country (2021-2026) & (USD Million)
List of Figures
Figure 1. Human Microbiome Based Drugs and Diagnostics Picture
Figure 2. Global Human Microbiome Based Drugs and Diagnostics Revenue Market Share by Type in 2020
Figure 3. Therapeutics
Figure 4. Diagnostics
Figure 5. Human Microbiome Based Drugs and Diagnostics Revenue Market Share by Application in 2020
Figure 6. Clinical Research Institutes Picture
Figure 7. Hospital Picture
Figure 8. Surgical Centers Picture
Figure 9. Others Picture
Figure 10. Global Human Microbiome Based Drugs and Diagnostics Revenue, (USD Million): 2020 VS 2021 VS 2026
Figure 11. Global Human Microbiome Based Drugs and Diagnostics Revenue and Forecast (2016-2026) & (USD Million)
Figure 12. Global Human Microbiome Based Drugs and Diagnostics Revenue Market Share by Region (2016-2026)
Figure 13. Global Human Microbiome Based Drugs and Diagnostics Revenue Market Share by Region in 2020
Figure 14. North America Human Microbiome Based Drugs and Diagnostics Revenue (USD Million) and Growth Rate (2016-2026)
Figure 15. Europe Human Microbiome Based Drugs and Diagnostics Revenue (USD Million) and Growth Rate (2016-2026)
Figure 16. Asia-Pacific Human Microbiome Based Drugs and Diagnostics Revenue (USD Million) and Growth Rate (2016-2026)
Figure 17. South America Human Microbiome Based Drugs and Diagnostics Revenue (USD Million) and Growth Rate (2016-2026)
Figure 18. Middle East and Africa Human Microbiome Based Drugs and Diagnostics Revenue (USD Million) and Growth Rate (2016-2026)
Figure 19. Human Microbiome Based Drugs and Diagnostics Market Drivers
Figure 20. Human Microbiome Based Drugs and Diagnostics Market Restraints
Figure 21. Human Microbiome Based Drugs and Diagnostics Market Trends
Figure 22. Second Genome Recent Developments and Future Plans
Figure 23. Enterome Bioscience Recent Developments and Future Plans
Figure 24. Yakult Recent Developments and Future Plans
Figure 25. Dowdupont Recent Developments and Future Plans
Figure 26. Vedanta BioSciences Recent Developments and Future Plans
Figure 27. Metabiomics Corporation Recent Developments and Future Plans
Figure 28. ViThera Pharmaceuticals Recent Developments and Future Plans
Figure 29. MicroBiome Therapeutics Recent Developments and Future Plans
Figure 30. Osel Recent Developments and Future Plans
Figure 31. Merck Recent Developments and Future Plans
Figure 32. Global Human Microbiome Based Drugs and Diagnostics Revenue Share by Players in 2020
Figure 33. Human Microbiome Based Drugs and Diagnostics Market Share by Company Type (Tier 1, Tier 2 and Tier 3)
Figure 34. Global Top 3 Players Human Microbiome Based Drugs and Diagnostics Revenue Market Share in 2020
Figure 35. Global Top 10 Players Human Microbiome Based Drugs and Diagnostics Revenue Market Share in 2020
Figure 36. Key Players Market Share Trend (Top 3 Market Share: 2019 VS 2020 VS 2021)
Figure 37. Global Human Microbiome Based Drugs and Diagnostics Revenue Share by Type in 2020
Figure 38. Global Human Microbiome Based Drugs and Diagnostics Market Share Forecast by Type (2021-2026)
Figure 39. Global Human Microbiome Based Drugs and Diagnostics Revenue Share by Application in 2020
Figure 40. Global Human Microbiome Based Drugs and Diagnostics Market Share Forecast by Application (2021-2026)
Figure 41. North America Human Microbiome Based Drugs and Diagnostics Sales Market Share by Type (2016-2026)
Figure 42. North America Human Microbiome Based Drugs and Diagnostics Sales Market Share by Application (2016-2026)
Figure 43. North America Human Microbiome Based Drugs and Diagnostics Revenue Market Share by Country (2016-2026)
Figure 44. United States Human Microbiome Based Drugs and Diagnostics Revenue and Growth Rate (2016-2026) & (USD Million)
Figure 45. Canada Human Microbiome Based Drugs and Diagnostics Revenue and Growth Rate (2016-2026) & (USD Million)
Figure 46. Mexico Human Microbiome Based Drugs and Diagnostics Revenue and Growth Rate (2016-2026) & (USD Million)
Figure 47. Europe Human Microbiome Based Drugs and Diagnostics Sales Market Share by Type (2016-2026)
Figure 48. Europe Human Microbiome Based Drugs and Diagnostics Sales Market Share by Application (2016-2026)
Figure 49. Europe Human Microbiome Based Drugs and Diagnostics Revenue Market Share by Country (2016-2026)
Figure 50. Germany Human Microbiome Based Drugs and Diagnostics Revenue and Growth Rate (2016-2026) & (USD Million)
Figure 51. France Human Microbiome Based Drugs and Diagnostics Revenue and Growth Rate (2016-2026) & (USD Million)
Figure 52. United Kingdom Human Microbiome Based Drugs and Diagnostics Revenue and Growth Rate (2016-2026) & (USD Million)
Figure 53. Russia Human Microbiome Based Drugs and Diagnostics Revenue and Growth Rate (2016-2026) & (USD Million)
Figure 54. Italy Human Microbiome Based Drugs and Diagnostics Revenue and Growth Rate (2016-2026) & (USD Million)
Figure 55. Asia-Pacific Human Microbiome Based Drugs and Diagnostics Sales Market Share by Type (2016-2026)
Figure 56. Asia-Pacific Human Microbiome Based Drugs and Diagnostics Sales Market Share by Application (2016-2026)
Figure 57. Asia-Pacific Human Microbiome Based Drugs and Diagnostics Revenue Market Share by Region (2016-2026)
Figure 58. China Human Microbiome Based Drugs and Diagnostics Revenue and Growth Rate (2016-2026) & (USD Million)
Figure 59. Japan Human Microbiome Based Drugs and Diagnostics Revenue and Growth Rate (2016-2026) & (USD Million)
Figure 60. South Korea Human Microbiome Based Drugs and Diagnostics Revenue and Growth Rate (2016-2026) & (USD Million)
Figure 61. India Human Microbiome Based Drugs and Diagnostics Revenue and Growth Rate (2016-2026) & (USD Million)
Figure 62. Southeast Asia Human Microbiome Based Drugs and Diagnostics Revenue and Growth Rate (2016-2026) & (USD Million)
Figure 63. Australia Human Microbiome Based Drugs and Diagnostics Revenue and Growth Rate (2016-2026) & (USD Million)
Figure 64. South America Human Microbiome Based Drugs and Diagnostics Sales Market Share by Type (2016-2026)
Figure 65. South America Human Microbiome Based Drugs and Diagnostics Sales Market Share by Application (2016-2026)
Figure 66. South America Human Microbiome Based Drugs and Diagnostics Revenue Market Share by Country (2016-2026)
Figure 67. Brazil Human Microbiome Based Drugs and Diagnostics Revenue and Growth Rate (2016-2026) & (USD Million)
Figure 68. Argentina Human Microbiome Based Drugs and Diagnostics Revenue and Growth Rate (2016-2026) & (USD Million)
Figure 69. Middle East and Africa Human Microbiome Based Drugs and Diagnostics Sales Market Share by Type (2016-2026)
Figure 70. Middle East and Africa Human Microbiome Based Drugs and Diagnostics Sales Market Share by Application (2016-2026)
Figure 71. Middle East and Africa Human Microbiome Based Drugs and Diagnostics Revenue Market Share by Country (2016-2026)
Figure 72. Turkey Human Microbiome Based Drugs and Diagnostics Revenue and Growth Rate (2016-2026) & (USD Million)
Figure 73. Saudi Arabia Human Microbiome Based Drugs and Diagnostics Revenue and Growth Rate (2016-2026) & (USD Million)
Figure 74. UAE Human Microbiome Based Drugs and Diagnostics Revenue and Growth Rate (2016-2026) & (USD Million)
Figure 75. Methodology
Figure 76. Research Process and Data Source
世界のヒトマイクロバイオームモジュレーター市場 2021：企業別、地域別、種類・用途別 The Human Microbiome Modulators market report provides a detailed analysis of global market size, regional and country-level market size, segmentation market growth, market share, competitive Landscape, sales analysis, impact of domestic and global market players, value chain optimization, trade reg…- 世界のマイクロバイオーム診断市場 2021：企業別、地域別、種類・用途別 The Microbiome Diagnostics market report provides a detailed analysis of global market size, regional and country-level market size, segmentation market growth, market share, competitive Landscape, sales analysis, impact of domestic and global market players, value chain optimization, trade regulati…
- 世界のヒトマイクロバイオームモジュレーター市場予測（～2024年） The human microbiota is an aggregate of microorganisms residing in the human body, mostly in the gastrointestinal tract. Scope of the Report: The global Human Microbiome Modulators market is valued at xx million USD in 2018 and is expected to reach xx million USD by the end of 2024, growing at a CAG…
- 微生物叢治療薬市場：世界及び中国市場分析・予測（～2024年） Microbiome Therapeutics Market Insights 2019, Global and Chinese Scenario is a professional and in-depth study on the current state of the global Microbiome Therapeutics industry with a focus on the Chinese market. The report provides key statistics on the market status of the Microbiome Therapeutic…
- NGS（次世代シーケンシング）ベース診断市場：世界及び中国市場分析・予測（～2024年） NGS Based Diagnostics Market Insights 2019, Global and Chinese Scenario is a professional and in-depth study on the current state of the global NGS Based Diagnostics industry with a focus on the Chinese market. The report provides key statistics on the market status of the NGS Based Diagnostics manu…